Advancing Novel SARS-CoV-2 Therapeutic Antibodies

Twist recently conducted pre-clinical studies aimed at understanding the protective nature of our antibody leads in vivo against COVID-19. The data show that TB202-3 and TB202-63, both single-domain VHH “nanobodies” protect against weight loss at the lowest dose of 1 mg/kg in preclinical hamster challenge models. In addition, TB181-36, an IgG antibody discovered through Twist’s collaboration with Vanderbilt University Medical Center (VUMC), was found to protect against weight loss at 5 mg/kg and 10 mg/kg.

Covered in this Technical Document

Learn about Twist Biopharma’s program to develop therapeutic antibodies for COVID-19

See the binding and specificity data of this set of antibody molecules

See the latest data showing strong neutralization of the SARS-CoV-2 Virus in an animal model

Genes

Oligo Pools

NGS Target Enrichment Solutions

Variant Libraries

Synthetic Controls

Antibody Discovery

Advancing Novel SARS-CoV-2 Therapeutic Antibodies

Related Resources

Antibody Discovery At The Edge Of Impossible